This is a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group,
fixed dose study to assess the efficacy and safety of SPN-812 ER in treatment of children
aged 6-12 years with ADHD. The primary objective is to assess the effect of SPN-812 ER in
reducing ADHD symptoms. This will be measured using the ADHD-RS-IV rating scale.